Eicosapentaenoic Acid (EPA)

What it is

Eicosapentaenoic acid (EPA) is a 20-carbon polyunsaturated omega-3 fatty acid harvested primarily from marine cold-water fish and microalgae. In dietary supplements, EPA is purified into concentrated triglyceride or ethyl ester oil formulations. It serves as a precursor to odd-numbered eicosanoids (3-series prostaglandins and thromboxanes, 5-series leukotrienes) and specialized pro-resolving mediators (resolvins), which physiologically counterbalance pro-inflammatory arachidonic acid cascades.

Also known as: EPA Omega-3, Omega-3 EPA

What it does

• Supports cardiovascular health by maintaining normal plasma triglyceride levels and endothelial function.
• Helps modulate cellular inflammatory cascades and balanced eicosanoid production.
• Supports joint comfort and systemic vascular wellness.

Amplified by probiotics

Probiotic bacteria inhabiting the intestinal lumen exert active bile-salt hydrolase (BSH) enzymatic activity that alters the conjugation state of luminal bile acids. This enzymatic modification directly regulates lipid emulsification and mixed micelle formation required for hydrophobic EPA molecules to cross the apical enterocyte brush border. Concurrently, probiotic fermentative metabolites, specifically short-chain fatty acids (SCFAs) like butyrate, nourish colonocytes, maintain apical tight junction protein expression, and suppress mucosal pro-inflammatory cytokines. By reducing intestinal vascular barrier hyperpermeability and preventing systemic endotoxemia, live probiotics establish a favorable non-inflammatory gut microenvironment. This luminal stability acts in direct physiological synergy with EPA-derived specialized pro-resolving mediators (resolvins) to downregulate systemic inflammatory signaling.

Typical dose

250–2000 mg/day

The evidence

Numerous clinical trials demonstrate that EPA supplementation significantly reduces serum triglycerides and improves vascular reactivity (Mozaffarian 2011, J Am Coll Cardiol). Human intervention studies confirm that EPA incorporation into cell membranes suppresses pro-inflammatory eicosanoid synthesis and promotes inflammatory resolution (Calder 2015, Biochim Biophys Acta).

1. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047-2067. PubMed ↗
2. Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015;1851(4):469-484. PubMed ↗

Safety & who should check first

High safety profile; supplemental intakes up to 5 g/day combined EPA/DHA are well tolerated. May slightly potentiate anticoagulant medications at very high doses; safe in pregnancy.